Platelet Glycoprotein IIb/IIIa Inhibitors in Cardiovascular Disease

1. Front Matter

   Pages i-x

   PDF

2. Basic Principles

   1. Front Matter

      Pages 1-1

      PDF

   2. Thrombosis in Acute Coronary Syndromes and Coronary Interventions

      • Thaddeus R. Tolleson, Robert A. Harrington

      Pages 3-21

   3. Platelet Adhesion

      • Edward E. Plow

      Pages 23-37

   4. Glycoprotein IIb/IIIa in Platelet Aggregation and Acute Arterial Thrombosis

      • Patrick Andre, David R. Phillips

      Pages 39-71

   5. Glycoprotein IIb/IIIa Antagonists

      • Barry S. Coller

      Pages 73-101

3. Glycoprotein IIb/IIIa Blockade During Coronary Intervention

   1. Front Matter

      Pages 103-103

      PDF

   2. Abciximab During Percutaneous Coronary Intervention

      • A. Michael Lincoff

      Pages 105-124

   3. Eptifibatide in Coronary Intervention

      • Jean-Pierre Deg, J. Conor O’Shea, James E. Tcheng

      Pages 125-146

   4. Tirofiban in Interventional Cardiology

      • Nicholas Valettas, Howard C. Herrmann

      Pages 147-166

   5. Overview of the Glycoprotein IIb/IIIa Interventional Trials

      • A. Michael Lincoff, Eric J. Topol

      Pages 167-199

4. Glycoprotein IIB/IIIA Blockade for Acute Ischemic Syndromes

   1. Front Matter

      Pages 201-201

      PDF

   2. The Use of Abciximab in Therapy-Resistant Unstable Angina

      • Marcel J. B. M. van den Brand, Maarten L. Simoons

      Pages 203-231

   3. Unstable Angina Trials

      • David J. Moliterno

      Pages 233-262

   4. Platelet Glycoprotein IIb/IIIa Inhibitors and an Invasive Strategy

      • Christopher P. Cannon

      Pages 263-273

   5. Glycoprotein IIb/IIIa Receptor Blockade in Myocardial Infarction

      • Franz-Josef Neumann

      Pages 275-287

   6. Glycoprotein IIb/IIIa Receptor Blockade in Acute Myocardial Infarction

      • Sorin J. Brener

      Pages 289-302

5. Practical Issues and Future Applications

   1. Front Matter

      Pages 303-303

      PDF

   2. Economics of Glycoprotein IIb/IIIa Inhibition

      • Daniel B. Mark

      Pages 305-319

   3. Platelet Monitoring and Interaction of Glycoprotein IIb/IIIa Antagonists with Other Antiplatelet Agents

      • Steven R. Steinhubl

      Pages 321-340

A. Michael Lincoff takes advantage of critically important new knowledge arising from recent clinical trials to update and expand his acclaimed Platelet Glycoprotein IIb/IIIa Inhibitors in Cardiovascular Disease. This substantially enhanced Second Edition contains new chapters on the role of GPIIb/IIIa blockade during acute coronary syndromes, on outcomes with chronic oral GPIIb/IIIa blockade following acute coronary syndromes, and on fibrinolytic therapy during acute myocardial infarctions. Additional enhancements include revised findings from the latest trials of GPIIb/IIIa inhibition during percutaneous coronary intervention, discussion of GPIIb/IIIa blockade with other platelet and thrombin inhibitors, and a review of the potential effects beyond inhibition of platelet aggregation. The book also explains the scientific basis of this therapy, evaluates its benefits and risks for patients, and summarizes detailed data from its various clinical trials.
Comprehensive and definitive, Platelet Glycoprotein IIb/IIIa Inhibitors in Cardiovascular Disease, Second Edition offers physicians, cardiologists, emergency room doctors, and basic scientists a complete and authoritative review of the state-of-the-art in glycoprotein IIb/IIIa receptor inhibitor use today.

• Stent
• cardiology
• cardiovascular
• emergency
• heart disease
• myocardial infarction
• pharmacology
• platelet
• vascular disease

"...provides the reader with extensive and profound information about this new class, based on data from completed and ongoing trials...can be recommended not only to cardiologists but to all clinicians and researchers interested in this field."
-Intensive Care Medicine

• Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, Cleveland, USA

  A. Michael Lincoff

Policies and ethics